Introduction
migraine, Migraine, CM
MIGRAINE, MIGRAINE
The global prevalence of migraine varies among studies, a recent update provides a summary estimate of 14% and shows a prevalence peak in mid-life [A recent global survey, “My Migraine Voice”, evaluated the social and economic impact of migraine in patients with ≥ 4 monthly migraine days who were receiving preventive treatment for EM or CM [Guidelines for clinical trials of migraine treatments recommend the use of Patient Reported Outcome (PRO) measures [Recently, the CONQUER study demonstrated the efficacy and safety of galcanezumab versus placebo in patients with EM or CM who had previously failed to benefit from or tolerate two to four standard-of-care categories of migraine preventive medications [